Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Halozyme Therapeutics Inc. Stories

2013-09-12 12:29:17

Editor Note: For more information about this release, please scroll to bottom. LONDON, September 12, 2013 /PRNewswire/ -- The U.S. equity market ended on a mixed note on Wednesday, September 11, 2013. The S&P 500 and the Dow Jones Industrial Average gained 0.31% and 0.89%, respectively, while the NASDAQ Composite fell by 0.11%. Shares in the biotechnology industry ended lower, even as the broader market finished on a mixed note. The major movers included Gilead Sciences...

2013-09-12 08:32:21

SAN DIEGO, Sept. 12, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with gemcitabine for the treatment of patients with stage IV metastatic pancreatic cancer will be presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO) in Amsterdam. Additional data, including progression free and overall survival by hyaluronan (HA) status, will be...

2013-09-02 00:20:34

SAN DIEGO, Sept. 2, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission has granted Roche European Union (EU) marketing authorization for the use of a time-saving subcutaneous (SC) formulation of Herceptin(®) (trastuzumab) for the treatment of HER2-positive breast cancer. This formulation utilizes Halozyme's recombinant human hyaluronidase (rHuPH20) and is administered in two to five minutes, rather than 30 to 90 minutes with...

2013-08-12 08:29:04

Editor Note: For more information about this release, please scroll to bottom NEW YORK, August 12, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), Exelixis, Inc. (NASDAQ: EXEL), Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), Puma Biotechnology, Inc. (NYSE: PBYI), and Halozyme Therapeutics, Inc. (NASDAQ: HALO). Today's readers may access these reports free of charge - including full price...

2013-08-07 16:28:02

SAN DIEGO, Aug. 7, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter and six months ended June 30, 2013. Financial highlights for the second quarter include revenues of $14.5 million and a net loss of $22.9 million or $0.20 per share. This compares to revenues of $7.8 million and a net loss of $14.0 million or $0.13 per share for the second quarter of 2012. (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)...

2013-08-06 08:29:03

LONDON, August 6, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. On Monday, August 5, 2013, the S&P 500 closed 0.15% lower at 1,707.14. Shares in biotechnology companies ended on a mixed note as the broader market edged lower. The major movers in the sector included Gilead Sciences Inc. (NASDAQ: GILD), InterMune Inc. (NASDAQ: ITMN), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), and Halozyme Therapeutics Inc. (NASDAQ:...

2013-08-01 08:34:00

SAN DIEGO, Aug. 1, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that following discussions with the Center for Biologics Evaluation and Research (CBER) division of the U.S. Food and Drug Administration, ViroPharma will be discontinuing their Phase 2 study of subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) with recombinant human hyaluronidase (rHuPH20). The discontinuation of the study is a precaution related to the emergence of an unexpected...

2013-07-31 16:29:00

SAN DIEGO, July 31, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2013 on Wednesday, August 7, 2013 at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the second quarter 2013. (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO) The call will be webcast...

2013-07-02 12:28:48

Editor Note: For more information about this release, please scroll to bottom. LONDON, July 2, 2013 /PRNewswire/ -- On Monday, July 1, 2013, shares in biotechnology companies ended mostly higher, tracking gains in the broader market. All three benchmark indices edged higher after investors digested better-than-expected U.S. economic data. The major movers in the industry included Gilead Sciences Inc. (NASDAQ: GILD), Halozyme Therapeutics Inc. (NASDAQ: HALO), Santarus Inc....

2013-06-30 12:20:10

Phase 2 study interim analysis indicates positive activity SAN DIEGO, June 30, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced interim results from a proof of concept Phase 1/2 clinical trial evaluating the activity and local tolerability of HTI-501, an investigational biologic, for use in aesthetic dermatology. The data were presented June 29, 2013 at the 9(th) Annual World Congress of Cosmetic Dermatology in Athens, Greece. (Logo:...